CA2317748C - Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection - Google Patents
Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection Download PDFInfo
- Publication number
- CA2317748C CA2317748C CA002317748A CA2317748A CA2317748C CA 2317748 C CA2317748 C CA 2317748C CA 002317748 A CA002317748 A CA 002317748A CA 2317748 A CA2317748 A CA 2317748A CA 2317748 C CA2317748 C CA 2317748C
- Authority
- CA
- Canada
- Prior art keywords
- microbial infection
- resistant
- medicament
- treated
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 59
- 229960004267 taurolidine Drugs 0.000 title claims abstract description 56
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 230000000813 microbial effect Effects 0.000 title claims abstract description 44
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229950007343 taurultam Drugs 0.000 title claims abstract description 27
- 239000004599 antimicrobial Substances 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 241000194032 Enterococcus faecalis Species 0.000 claims description 71
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 39
- 241000194031 Enterococcus faecium Species 0.000 claims description 30
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 26
- 108010059993 Vancomycin Proteins 0.000 claims description 25
- 229960003165 vancomycin Drugs 0.000 claims description 25
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 25
- 230000003115 biocidal effect Effects 0.000 claims description 22
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 20
- 241000295644 Staphylococcaceae Species 0.000 claims description 20
- 229960003085 meticillin Drugs 0.000 claims description 20
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 15
- 239000003242 anti bacterial agent Substances 0.000 claims description 14
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 238000013268 sustained release Methods 0.000 claims description 7
- 239000012730 sustained-release form Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 210000002421 cell wall Anatomy 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 11
- 239000002158 endotoxin Substances 0.000 abstract description 8
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract description 2
- 206010041925 Staphylococcal infections Diseases 0.000 abstract description 2
- 231100000776 exotoxin Toxicity 0.000 abstract description 2
- 239000002095 exotoxin Substances 0.000 abstract description 2
- 230000000415 inactivating effect Effects 0.000 abstract description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 11
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 206010011409 Cross infection Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001937 non-anti-biotic effect Effects 0.000 description 5
- 231100000699 Bacterial toxin Toxicity 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 206010034133 Pathogen resistance Diseases 0.000 description 4
- 239000000688 bacterial toxin Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003326 cloxacillin Drugs 0.000 description 3
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 206010062631 Cholecystitis infective Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010069802 Device related sepsis Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- -1 capric Chemical compound 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 229940048400 fucidin Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940028817 methitest Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/004,063 | 1998-01-08 | ||
| US09/004,063 US5972933A (en) | 1998-01-08 | 1998-01-08 | Method of treating microbial infections |
| PCT/GB1999/000028 WO1999034805A1 (en) | 1998-01-08 | 1999-01-06 | Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2317748A1 CA2317748A1 (en) | 1999-07-15 |
| CA2317748C true CA2317748C (en) | 2008-07-08 |
Family
ID=21708954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002317748A Expired - Fee Related CA2317748C (en) | 1998-01-08 | 1999-01-06 | Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5972933A (enExample) |
| EP (1) | EP1044006B1 (enExample) |
| JP (2) | JP2002500189A (enExample) |
| AU (1) | AU757294B2 (enExample) |
| CA (1) | CA2317748C (enExample) |
| DE (1) | DE69934294T2 (enExample) |
| ES (1) | ES2274614T3 (enExample) |
| WO (1) | WO1999034805A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117868A (en) * | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
| CA2393252A1 (en) | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
| CN100519525C (zh) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| US20020004502A1 (en) * | 2000-01-05 | 2002-01-10 | Redmond H. Paul | Treatment of inflammatory bowel disease |
| EP1450814B1 (en) | 2001-10-01 | 2016-11-30 | Geistlich Pharma AG | Methods of inhibiting metastases |
| US7240441B2 (en) * | 2004-02-12 | 2007-07-10 | Mccoy Ted | Excavator thumb for use with excavator equipment |
| JP5227185B2 (ja) * | 2006-01-06 | 2013-07-03 | エド・ガイストリッヒ・ゼーネ・アクチェンゲゼルシャフト・フュール・ヒェミッシェ・インドゥストリー | 放射線照射された組成物並びにタウロリジン及び／又はタウルルタムを併用する癌の放射線治療 |
| US20080008734A1 (en) * | 2006-07-05 | 2008-01-10 | Perrault James J | Reduction of skin irritation caused by biomedical electrodes |
| WO2011097646A1 (en) * | 2010-02-08 | 2011-08-11 | Maxlinear, Inc. | Methods and apparatus for intelligent power reduction in communications systems |
| CN103118669B (zh) * | 2010-06-01 | 2016-01-13 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
| US20130296223A1 (en) * | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| US9951097B2 (en) | 2012-12-04 | 2018-04-24 | The Board Of Trustees Of The University Of Illinois | Antibacterial compounds targeting isoprenoid biosynthesis |
| EP3377067A4 (en) * | 2015-10-07 | 2019-07-31 | Cormedix Inc. | SKIN-PENETRATING FORMULATION OF TAUROLIDINE |
| WO2018129061A1 (en) * | 2017-01-05 | 2018-07-12 | Cormedix Inc. | Antimicrobial delivery system for the prevention and treatment of infections in the colon |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1124285A (en) * | 1964-10-06 | 1968-08-21 | Geistlich Soehne Ag | Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them |
| GB1557163A (en) * | 1975-06-24 | 1979-12-05 | Geistlich Soehne Ag | Dental care preparations |
| US4107305A (en) * | 1975-08-04 | 1978-08-15 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Treatment of endotoxaemia |
| US4002889A (en) * | 1975-12-08 | 1977-01-11 | Servo Corporation Of America | Self-cleaning label for automatic object identification system |
| US4337251A (en) * | 1979-05-09 | 1982-06-29 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of avoiding and removing adhesions |
| CA1190855A (en) * | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
| GB8328073D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
| GB8328074D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compositions |
| GB8328111D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
| DE3506288A1 (de) * | 1984-09-06 | 1986-03-13 | Johannes 7900 Ulm Reinmüller | Vorrichtung zum einlegen in wunden und wundhoehlen |
| GB8424518D0 (en) * | 1984-09-28 | 1984-11-07 | Geistlich Sohne Af Fur Chemisc | Chemical compounds |
| GB8514055D0 (en) * | 1985-06-04 | 1985-07-10 | Geistlich Soehne Ag | Chemical substance |
| DE3533612A1 (de) * | 1985-09-20 | 1987-04-02 | Johannes Reinmueller | Neuartige verwendung von taurolin |
| US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| GB8813033D0 (en) * | 1988-06-02 | 1988-07-06 | Geistlich Soehne Ag | Chemical compound |
| US5304540A (en) * | 1988-06-22 | 1994-04-19 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
| GB8827986D0 (en) * | 1988-11-30 | 1989-01-05 | Geistlich Soehne Ag | Chemical product |
| CA2031803C (en) * | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
| GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| US5187082A (en) * | 1990-08-16 | 1993-02-16 | Eli Lilly And Company | Process for producing A83850 antibiotics |
| AU665188B2 (en) * | 1991-04-15 | 1995-12-21 | Applied Microbiology, Inc | Pharmaceutical compositions against gastric disorders |
| DE69104608T2 (de) * | 1991-07-04 | 1995-02-16 | Weissenfluh Hawe Neos | Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis. |
| GB9216155D0 (en) * | 1992-07-30 | 1992-09-09 | Geistlich Soehne Ag | Treatment of dentoalveolar infections |
| US5650320A (en) * | 1994-04-20 | 1997-07-22 | University Of Alabama At Birmingham Research Foundation | Lanthionine antibiotic compositions and methods |
| GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
| AU710109B2 (en) * | 1996-01-16 | 1999-09-16 | Ap Pharma, Inc. | Topical delivery of drugs to the lower gastrointestinal tract |
-
1998
- 1998-01-08 US US09/004,063 patent/US5972933A/en not_active Expired - Lifetime
-
1999
- 1999-01-06 AU AU18844/99A patent/AU757294B2/en not_active Ceased
- 1999-01-06 JP JP2000527254A patent/JP2002500189A/ja active Pending
- 1999-01-06 EP EP99900217A patent/EP1044006B1/en not_active Expired - Lifetime
- 1999-01-06 ES ES99900217T patent/ES2274614T3/es not_active Expired - Lifetime
- 1999-01-06 DE DE69934294T patent/DE69934294T2/de not_active Expired - Lifetime
- 1999-01-06 CA CA002317748A patent/CA2317748C/en not_active Expired - Fee Related
- 1999-01-06 WO PCT/GB1999/000028 patent/WO1999034805A1/en not_active Ceased
-
2010
- 2010-04-01 JP JP2010084729A patent/JP5469511B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU757294B2 (en) | 2003-02-13 |
| JP5469511B2 (ja) | 2014-04-16 |
| EP1044006B1 (en) | 2006-12-06 |
| JP2010174032A (ja) | 2010-08-12 |
| DE69934294D1 (de) | 2007-01-18 |
| CA2317748A1 (en) | 1999-07-15 |
| WO1999034805A1 (en) | 1999-07-15 |
| ES2274614T3 (es) | 2007-05-16 |
| US5972933A (en) | 1999-10-26 |
| AU1884499A (en) | 1999-07-26 |
| JP2002500189A (ja) | 2002-01-08 |
| DE69934294T2 (de) | 2007-07-05 |
| EP1044006A1 (en) | 2000-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5469511B2 (ja) | 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用 | |
| DK1879655T3 (en) | Pharmaceutical composition comprising an antibacterial agent and an active substance selected from carveol, carvacrol, alpha-ionone, beta-ionone, and thymol | |
| AU2009225281A1 (en) | Methods and reagents for treating infections of clostridium difficile and diseases associate therewith | |
| CA3035686C (en) | New use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection | |
| US20180256592A1 (en) | Antibacterial compositions | |
| US20040147441A1 (en) | Methods and reagents for preventing bacteremias | |
| JP2002500189A5 (enExample) | ||
| EA016803B1 (ru) | Лечение инфекционных заболеваний | |
| US20070009566A1 (en) | Method and apparatus for treating bacterial infections in devices | |
| US6858589B2 (en) | Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria | |
| US10905691B2 (en) | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection | |
| Slack et al. | The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection | |
| Vazqueza et al. | Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits | |
| US6475992B2 (en) | Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria | |
| Andersen et al. | Pivmecillinam in the treatment of therapy resistant urinary tract infections: A comparison with pivmecillinam, pivampicillin and their combination | |
| EP1368010A2 (en) | Antibacterial compositions which contain oxapenem-3-carboxylic acids and antibiotics | |
| WO2018039087A1 (en) | Antimicrobial drug methods of use & therapeutic compositions | |
| IL134597A (en) | Use of an antibiotic compound for the preparation of a drug for the treatment of diseases that can be attributed to Staphylococcus aureus | |
| HK40053249A (en) | Use of rifamycin-quinolizidone coupling molecule and pharmaceutically acceptable salt thereof | |
| Labu et al. | Application of antimicrobial agents and its unwanted effects | |
| BR122024018415A2 (pt) | Usos de derivados de triazolo(4,5-d) pirimidina, e método para neutralização de bactérias ou prevenção do crescimento bacteriano na formação de biofilme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190107 |